Tvardi Therapeutics GAAP EPS of -$0.59 beats by $0.22
Source: SeekingAlpha
2025-11-13 16:38:46 ET
More on Tvardi Therapeutics
- Tvardi Therapeutics: 'Sell' Rating On IPF Drug TTI-101 Advancement Uncertainty
- Tivardi downgraded at Raymond James following TTI-101 trial failure
- Tivardi tanks on phase 2 data of TTI-101 in idiopathic pulmonary fibrosis
- Seeking Alpha’s Quant Rating on Tvardi Therapeutics
- Historical earnings data for Tvardi Therapeutics
Read the full article on Seeking Alpha
For further details see:
Tvardi Therapeutics GAAP EPS of -$0.59 beats by $0.22
Tvardi Therapeutics Inc.
NASDAQ: TVRD
TVRD Trading
1.3% G/L:
$3.90 Last:
7,367 Volume:
$3.90 Open:
TVRD Latest News
January 08, 2026 04:05:00 pm
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026 08:00:00 am
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights
November 18, 2025 08:00:00 am
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 13, 2025 04:01:00 pm
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
TVRD Stock Data
$35,461,480
6,591,332
N/A
22
N/A
Biotechnology & Life Sciences
Healthcare
US
Sugar Land
